RE:RE:RE:RE:RE:What's bringing us down ? Or, Aducanumab is just one of many failures in the field of ACH, which neither proves nor disproves it. Taken collectively though there have been so many failures that there is still no theory arising from the hypothesis.
Goldstein's hypothesis is that his incompetence as our CEO is excusable because Aducanumab was in limbo, the implication being that his many quality-investor connections would more than pay off his bloated consulting fees once Aducanumab rescued the entire ACH field with some modest efficacy.
Cashman's hypothesis is more like protein misfolding is at the root of or a critical step in many neurological diseases. This is what drives Promis' platform, but it doesn't provide Goldstein any excuse.